PDL BIOPHARMA INC's ticker is PDLI and the CUSIP is 69329Y104. A total of 215 filers reported holding PDL BIOPHARMA INC in Q3 2015. The put-call ratio across all filers is 0.44 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $476,000 | 0.0% | 161,998 | 0.0% | 0.02% | 0.0% |
| Q1 2018 | $476,000 | -85.2% | 161,998 | -86.2% | 0.02% | -85.3% |
| Q4 2017 | $3,222,000 | -17.4% | 1,175,779 | +2.2% | 0.12% | -18.9% |
| Q3 2017 | $3,902,000 | +25.1% | 1,150,887 | -8.9% | 0.14% | +26.5% |
| Q2 2017 | $3,120,000 | +15.3% | 1,262,960 | +5.9% | 0.11% | +17.7% |
| Q1 2017 | $2,706,000 | -20.4% | 1,192,086 | +125.4% | 0.10% | +10.3% |
| Q2 2015 | $3,400,000 | -13.2% | 528,809 | -5.1% | 0.09% | -12.1% |
| Q1 2015 | $3,919,000 | -14.4% | 557,044 | -6.2% | 0.10% | +2.1% |
| Q4 2014 | $4,576,000 | -9.5% | 593,614 | -12.3% | 0.10% | -4.0% |
| Q3 2014 | $5,057,000 | -15.2% | 677,033 | +9.9% | 0.10% | -15.1% |
| Q2 2014 | $5,965,000 | +229.6% | 616,155 | +182.9% | 0.12% | +183.3% |
| Q1 2014 | $1,810,000 | +28.8% | 217,820 | +30.9% | 0.04% | +27.3% |
| Q4 2013 | $1,405,000 | – | 166,450 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Nine Chapters Capital Management LLC | 119,700 | $254,000 | 0.43% |
| GSA CAPITAL PARTNERS LLP | 1,587,756 | $3,366,000 | 0.20% |
| AMERICAFIRST CAPITAL MANAGEMENT, LLC | 60,901 | $129,110,000 | 0.14% |
| Acrospire Investment Management LLC | 129,480 | $274,000 | 0.11% |
| SECOR Capital Advisors, LP | 410,323 | $870,000 | 0.11% |
| RBF Capital, LLC | 251,421 | $540,000 | 0.08% |
| Park West Asset Management LLC | 400,000 | $848,000 | 0.07% |
| MACKENZIE FINANCIAL CORP | 4,687,825 | $9,938,000 | 0.06% |
| CIGNA INVESTMENTS INC /NEW | 261,533 | $554,000,000 | 0.06% |
| ACADIAN ASSET MANAGEMENT LLC | 5,503,285 | $11,665,000 | 0.06% |